A Deloitte Recap LLC analysis of 2012 biopharma dealmaking activity suggested a seller's market for Phase II assets, with median up-front cash of $35 million for market rights in transactions involving at least one major territory, up from a median of $30 million during the 2007-2011 time frame. However, market rights at other stages, including approval, lagged, as did the total deal flow.
After seven years of development, NuPathe Inc. finally received a green light from the FDA for its sumatriptan patch, branded Zecuity (sumatriptan iontophoretic transdermal system), for the acute treatment of migraine with or without aura in adults.
The Pharmaceutical Research and Manufacturers of America (PhRMA) served up two reports Thursday touting U.S. biopharma's "innovative and robust" pipeline of some 5,400 new molecular entities (NMEs), including more than 800 in Phase III studies.
Globally, up to 520 million people may suffer from food allergies, according to the World Allergy Organization, and the prevalence in the industrialized world has been rising for 50 years.
Aileron Therapeutics Inc. secured a second tranche of $12 million in its Series D financing, bringing the total round to $42 million and positioning its lead stapled peptide drug, ALRN-5281, to enter the clinic in orphan endocrine disorders.
The annual J.P. Morgan Healthcare Conference is perhaps more renowned for the dealmaking that occurs on the periphery of San Francisco's Westin St. Francis than for the news and views expressed within the hotel's hallowed halls.
SAN FRANCISCO – A trio of biotechs facing key clinical and regulatory reckonings in 2013 served up news and predictions Wednesday morning at the J.P. Morgan Healthcare Conference.
Ron Bentsur, CEO of Keryx Biopharmaceuticals Inc., disappointed some attendees on the final morning of the J.P. Morgan Healthcare Conference when he acknowledged the company is still waiting for Phase III data on Zerenex (ferric citrate) in end-stage renal disease (ESRD) patients with hyperphosphatemia.
SAN FRANCISCO – Ironwood Pharmaceuticals Inc. played to a packed house Monday afternoon following the luncheon keynote by journalist Bob Woodward at the J.P. Morgan Healthcare Conference.
SAN FRANCISCO – Improving economic indicators portending a positive year for biotech was the early theme of the 31st annual J.P. Morgan Healthcare Conference.
